DR. JAMES FRANK LIST, M.D.
Medical Practice at Jefferson Rd, Princeton, NJ
License number
New Jersey 156932
Category
Osteopathic Medicine
Type
Internal Medicine
License number
New Jersey 156932
Category
Osteopathic Medicine
Type
Endocrinology, Diabetes & Metabolism
License number
New Jersey 156932
Category
Medical Practice
Type
Pediatrics
Address
Address
280 Jefferson Rd, Princeton, NJ 08540
Phone
(609) 924-1381
Personal information
See more information about JAMES FRANK LIST at radaris.comName
Address
Phone
605 Jefferson St APT 1, Hoboken, NJ 07030
48 Brunswick Ave, Metuchen, NJ 08840
7 Glenmont Rd, White Hse Sta, NJ 08889
49 Ford Rd, Landing, NJ 07850
10 Middlesex Vlg #10B, Middlesex, NJ 08846
Professional information
See more information about JAMES FRANK LIST at trustoria.com
Dr. James F List, Princeton NJ - MD (Doctor of Medicine)
Dr. James F List, Princeton NJ - MD (Doctor of Medicine)
Specialties:
Endocrinology, Diabetes & Metabolism
Address:
3551 Lawrenceville Rd, Princeton 08540
Certifications:
Diabetes, Metabolism & Endocrinology, 2002, Internal Medicine, 2000, Pediatrics, 2000
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
University of Mn Med Sch
Graduated: 1993
Harvard Med Prog
Massachusetts General Hospital
University of Mn Med Sch
Graduated: 1993
Harvard Med Prog
Massachusetts General Hospital
Use Of Glp-1, Glp-1 Derivatives Or Glp-1 Fragments For Skin Regeneration, Stimulation Of Hair Growth, Or Treatment Of Diabetes
Use Of Glp-1, Glp-1 Derivatives Or Glp-1 Fragments For Skin Regeneration, Stimulation Of Hair Growth, Or Treatment Of Diabetes
US Patent:
2009020, Aug 13, 2009
Filed:
Aug 22, 2006
Appl. No.:
12/064525
Inventors:
Joel F. Habener - Newton Centre MA, US
James F. List - Princeton NJ, US
Svetlana Mojsov - New York NY, US
James F. List - Princeton NJ, US
Svetlana Mojsov - New York NY, US
Assignee:
The General Hospital Corporation - Boston MA
International Classification:
A61K 35/12, A61K 38/16, G01N 33/53
US Classification:
424 937, 514 12, 435 71
Abstract:
The present invention relates to the use of GLP-I, GLP-I derivatives or GLP-I fragments for skin regeneration or hair growth in mammals. As used for skin regeneration, GLP-I, GLP-I derivatives or GLP-I fragments can be applied to dermal wounds including burns, lacerations, cuts and scrapes. As used for hair growth, GLP-I, GLP-I derivatives or GLP-I fragments can be applied to humans suffering from alopecia, or baldness. GLP-I, GLP-I derivatives or GLP-I fragments can also be used to stimulate hair growth in animals raised for their pelts. GLP-I, GLP-I derivatives or GLP-I fragments can also be used in the redifferentiation of endothelial or skin cells into insulin producing cells, as a treatment for patients suffering from diabetes.
Methods For Treating Type 2 Diabetes In Patients Resistant To Previous Treatment With Other Anti-Diabetic Drugs Employing An Sglt2 Inhibitor And Compositions Thereof
Methods For Treating Type 2 Diabetes In Patients Resistant To Previous Treatment With Other Anti-Diabetic Drugs Employing An Sglt2 Inhibitor And Compositions Thereof
US Patent:
2012007, Mar 22, 2012
Filed:
May 26, 2010
Appl. No.:
13/321103
Inventors:
Paul Strumph - Pennington NJ, US
Stephanie Moran - Princeton NJ, US
James List - Princeton NJ, US
Stephanie Moran - Princeton NJ, US
James List - Princeton NJ, US
Assignee:
ASTRAZENECA UK LIMITED - London
BRISTOL-MYERS SQUIBB COMPANY - Princeton NJ
BRISTOL-MYERS SQUIBB COMPANY - Princeton NJ
International Classification:
A61K 38/28, A61K 38/18, A61P 3/10, A61P 3/04, A61P 7/10, A61P 9/10, A61P 7/02, A61P 9/12, A61P 39/06, A61K 31/7034, A61P 3/06
US Classification:
514 53, 514 23, 514 65, 514 84
Abstract:
The invention provides methods for treating a patient having type 2 diabetes who has failed on previous regimens of one or more oral and/or injectable anti-diabetic agents, which include the step of administering a therapeutically effective amount of an SGLT2 inhibitor alone or in combination with another anti-diabetic agent and/or other therapeutic agent to such patient. A pharmaceutical composition containing dapagliflozin or dapagliflozin-S-propylene glycol solvate and one or more diabetic agents and/or other therapeutic agents for use in the methods of the invention is also provided.
Use Of Glp-1, Glp-1 Derivatives Or Glp-1 Fragments For Skin Regeneration, Stimulation Of Hair Growth, Or Treatment Of Diabetes
Use Of Glp-1, Glp-1 Derivatives Or Glp-1 Fragments For Skin Regeneration, Stimulation Of Hair Growth, Or Treatment Of Diabetes
US Patent:
2012010, Apr 26, 2012
Filed:
Sep 2, 2011
Appl. No.:
13/224371
Inventors:
Joel F. Habener - Newton Centre MA, US
James F. List - Princeton NJ, US
Svetlana Mojsov - New York NY, US
James F. List - Princeton NJ, US
Svetlana Mojsov - New York NY, US
Assignee:
THE GENERAL HOSPITAL CORPORATION - Boston MA
International Classification:
A61K 38/26, A61M 37/00, A61M 5/00, A61P 17/14
US Classification:
514 117, 604 22, 604506
Abstract:
The present invention relates to the use of GLP-I, GLP-I derivatives or GLP-I fragments for skin regeneration or hair growth in mammals. As used for skin regeneration, GLP-I, GLP-I derivatives or GLP-I fragments can be applied to dermal wounds including burns, lacerations, cuts and scrapes. As used for hair growth, GLP-I, GLP-I derivatives or GLP-I fragments can be applied to humans suffering from alopecia, or baldness. GLP-I, GLP-I derivatives or GLP-I fragments can also be used to stimulate hair growth in animals raised for their pelts. GLP-I, GLP-I derivatives or GLP-I fragments can also be used in the redifferentiation of endothelial or skin cells into insulin producing cells, as a treatment for patients suffering from diabetes.
Methods For Treating Obesity Employing An Sglt2 Inhibitor
Methods For Treating Obesity Employing An Sglt2 Inhibitor
US Patent:
8088743, Jan 3, 2012
Filed:
Mar 21, 2008
Appl. No.:
12/053508
Inventors:
William N. Washburn - Titusville NJ, US
Jean Whaley - Bedminster NJ, US
Mario Maldonado - Basel, CH
James F. List - Princeton NJ, US
Frederick T. Fiedorek - Princeton NJ, US
Jean Whaley - Bedminster NJ, US
Mario Maldonado - Basel, CH
James F. List - Princeton NJ, US
Frederick T. Fiedorek - Princeton NJ, US
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
A61K 31/70
US Classification:
514 23, 514 25, 514 27, 514909
Abstract:
Methods are provided for treating obesity or causing weight loss in a mammalian subject or patient, wherein a therapeutically effective amount of an SGLT2 inhibitor alone or optionally in combination with another anti-obesity agent, is administered to a mammalian subject or patient. In addition, a pharmaceutical composition is provided which comprises an SGLT2 inhibitor, alone or in combination with another anti-obesity agent, and a pharmaceutically acceptable carrier thereof.
Methods For Treating Obesity Employing An Sglt2 Inhibitor And Compositions Thereof
Methods For Treating Obesity Employing An Sglt2 Inhibitor And Compositions Thereof
US Patent:
2012007, Mar 29, 2012
Filed:
Dec 2, 2011
Appl. No.:
13/310097
Inventors:
William Washburn - Titusville NJ, US
Jean Whaley - Beminster NJ, US
Mario Maldonado - Basel, CH
James F. List - Princeton NJ, US
Frederick T. Fiedorek - Princeton NJ, US
Jean Whaley - Beminster NJ, US
Mario Maldonado - Basel, CH
James F. List - Princeton NJ, US
Frederick T. Fiedorek - Princeton NJ, US
Assignee:
BRISTOL-MYERS SQUIBB - Princeton NJ
International Classification:
A61K 38/18, A61P 3/04, A61K 31/7034
US Classification:
514 48, 514 23
Abstract:
Methods are provided for treating obesity or causing weight loss in a mammalian subject or patient, wherein a therapeutically effective amount of an SGLT2 inhibitor alone or optionally in combination with another anti-obesity agent, is administered to a mammalian subject or patient. In addition, a pharmaceutical composition is provided which comprises an SGLT2 inhibitor, alone or in combination with another anti-obesity agent, and a pharmaceutically acceptable carrier thereof.